Error loading player: No playable sources found

36751

Session II - Managing the Complexity of the CGTP Supply Chain

Date
June 6, 2022
This product is not available for individual purchase, but it is available as part of the following products:
Thumbnail for Cell & Gene Therapy Products 2022
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…

Cell, gene, and other novel therapies require carefully designed and well executed logistics solutions for supplying lifesaving medicine to patients. Biological material sourced and produced for autologous and allogeneic therapies must be strictly controlled for temperature, timeline, as well as chain of identity and custody. This complexity was expanded by the COVID pandemic which has caused disruption in supply of materials, as well as manufacturing and logistics processes. On the other hand, smart technologies, digital solutions, and innovative operation models have driven the rapid evolution of global CGT clinical and commercial distribution. This session will explore the following topics:
• Planning and ensuring manufacturing capacity to serve the patient/market need.
• Solving supply chain challenges for clinical and/or commercial cell therapy products.
• Case studies of digital solution (electronic system integration), smart technologies and operation model successfully applied in supply chain management.

Related Products

Thumbnail for Accelerate Your Viral Vector Analytics with Automated Tools from Bio-Techne
Accelerate Your Viral Vector Analytics with Automated Tools from Bio-Techne
Modern medicines call for modern technologies. Revolutionary cell and gene therapies offer significant promise to treat life-threatening diseases. Getting therapies to market quickly and efficiently requires accurate testing of critical quality attributes, including accurate viral vector analysis…
Thumbnail for Identity testing by NGS as a means of risk mitigation
Identity testing by NGS as a means of risk mitigation
Imagine that you just completed a manufacturing run for a mission critical gene therapy vector. All of your release testing is underway, and you are days away from releasing your product. Per regulatory guidelines, identity testing is performed to confirm the vector sequence is as expected…
Thumbnail for Session V - Potency Assays
Session V - Potency Assays
Potency is a critical quality attribute (CQA) for cell and gene therapy (CGT) medicinal products…